2010 Annual Meeting | Child Neurology II

Date Friday 04/16/10

Time 01:15 PM - 05:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type PM Half-Day Course

Director(s) Basil T. Darras, MD

Topic(s)

Learning Objectives Participants should be able to incorporate newer diagnostic and therapeutic approaches to the management of these categories of neurologic disease occurring in children and adolescents and should be aware of the practice parameters that apply.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Systems-based Practice

Recommended Audience Other, Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Event Timeline
01:15 PM - 01:55 PM		Neurobehavioral Disorders David K. Urion, MD, FAAN
01:55 PM - 02:35 PM		Movement Disorders Jonathan W. Mink, MD, PhD, FAAN
02:35 PM - 03:15 PM		Selection of New Antiepileptic Drugs Blaise F. Bourgeois, MD
03:15 PM - 03:30 PM		Questions and Answers
03:30 PM - 03:45 PM		Break
03:45 PM - 04:20 PM		Neuroimmunology Robert S. Rust, MD
04:20 PM - 04:55 PM		Pediatric Neuro-ophthalmology Grant Liu, MD, FAAN
04:55 PM - 05:00 PM		Questions and Answers

Faculty Disclosures
Jonathan W. Mink, MD, PhD, FAAN	The institution of Dr. Mink has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amicus. The institution of Dr. Mink has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene. Dr. Mink has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. Dr. Mink has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics. Dr. Mink has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Applied Therapeutics. Dr. Mink has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. The institution of Dr. Mink has received research support from Neurogene. The institution of Dr. Mink has received research support from NIH. Dr. Mink has received publishing royalties from a publication relating to health care. Dr. Mink has received personal compensation in the range of $500-$4,999 for serving as a Member, Study Section with NINDS.
David K. Urion, MD, FAAN	Dr. Urion has nothing to disclose.
Blaise F. Bourgeois, MD	No disclosure on file
Robert S. Rust, MD	No disclosure on file
Grant Liu, MD, FAAN	Dr. Liu has received publishing royalties from a publication relating to health care.
Basil T. Darras, MD	The institution of Dr. Darras has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amicus. Dr. Darras has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. The institution of Dr. Darras has received research support from National Institutes of Health/National Institute of Neurological Disorders and Stroke,. The institution of Dr. Darras has received research support from Slaney Family Fund for SMA. The institution of Dr. Darras has received research support from Spinal Muscular Atrophy Foundation. The institution of Dr. Darras has received research support from CureSMA. The institution of Dr. Darras has received research support from Working on Walking Fund . The institution of Dr. Darras has received research support from CHERISH, CS2/CS12 . The institution of Dr. Darras has received research support from Biogen for CS11. The institution of Dr. Darras has received research support from AveXis. The institution of Dr. Darras has received research support from Sarepta Pharmaceuticals. The institution of Dr. Darras has received research support from PTC Therapeutics. The institution of Dr. Darras has received research support from Roche. The institution of Dr. Darras has received research support from Santhera. The institution of Dr. Darras has received research support from Scholar Rock. The institution of Dr. Darras has received research support from Fibrogen. The institution of Dr. Darras has received research support from Summit. Dr. Darras has received publishing royalties from a publication relating to health care. Dr. Darras has received publishing royalties from a publication relating to health care.